Subcutaneous furosemide in advanced heart failure: has clinical practice run ahead of the evidence base?

Affiliations

Editorial

James M Beattie et al. BMJ Support Palliat Care. 2012 Mar.

. 2012 Mar;2(1):5-6.

doi: 10.1136/bmjspcare-2011-000199. Epub 2011 Nov 29.

¹ Department of Cardiology, Heart of England NHS Foundation Trust, Birmingham, UK; National Clinical Lead, NHS Heart Improvement.

No abstract available

Comment in

Subcutaneous furosemide as palliative treatment in patients with advanced and terminal-phase heart failure.
Galindo-Ocaña J, Romero-Mena J, Castillo-Ferrando JR, Aguilera-González C, Bernabeu-Wittel M, Ollero-Baturone M. Galindo-Ocaña J, et al. BMJ Support Palliat Care. 2013 Mar;3(1):7-9. doi: 10.1136/bmjspcare-2012-000296. Epub 2012 Dec 15. BMJ Support Palliat Care. 2013. PMID: 24644319 No abstract available.
Left ventricular systolic dysfunction is where the robust evidence base for heart failure therapy has evolved.
Beattie JM, Johnson MJ. Beattie JM, et al. BMJ Support Palliat Care. 2012 Jun;2(2):84. doi: 10.1136/bmjspcare-2012-000267. BMJ Support Palliat Care. 2012. PMID: 24654041 No abstract available.
Response to editorial on subcutaneous diuretics.
Satchithananda D, Ingram A, Hookey C. Satchithananda D, et al. BMJ Support Palliat Care. 2012 Jun;2(2):84-5. doi: 10.1136/bmjspcare-2012-000259. BMJ Support Palliat Care. 2012. PMID: 24654042 No abstract available.